Future clinical trials of new cancer drugs will be completed more quickly and efficiently as a result of the introduction of personalised medicine, according to researchers.
By identifying and treating particular genetic groups within the population, trials can be carried out with smaller numbers and less stringent evidence criteria, said speakers at the European Multidisciplinary Cancer Congress in Sweden, reported in Science Business.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.